These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7964689)
21. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Ilgin N; Zubieta J; Reich SG; Dannals RF; Ravert HT; Frost JJ Neurology; 1999 Apr; 52(6):1221-6. PubMed ID: 10214747 [TBL] [Abstract][Full Text] [Related]
22. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation. Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022 [TBL] [Abstract][Full Text] [Related]
23. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. Federico F; Simone IL; Lucivero V; De Mari M; Giannini P; Iliceto G; Mezzapesa DM; Lamberti P J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):239-42. PubMed ID: 9069478 [TBL] [Abstract][Full Text] [Related]
24. Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Maloteaux JM; Laterre EC; Laduron PM; Javoy-Agid F; Agid Y Mov Disord; 1988; 3(3):255-62. PubMed ID: 3193963 [TBL] [Abstract][Full Text] [Related]
25. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548 [TBL] [Abstract][Full Text] [Related]
26. Quantitative susceptibility mapping from basal ganglia and related structures: correlation with disease severity in progressive supranuclear palsy. Krishnan S; George SS; Radhakrishnan V; Raghavan S; Thomas B; Thulaseedharan JV; Puthenveedu DK Acta Neurol Belg; 2024 Feb; 124(1):151-160. PubMed ID: 37580639 [TBL] [Abstract][Full Text] [Related]
28. Subcortical Cho H; Choi JY; Hwang MS; Lee SH; Ryu YH; Lee MS; Lyoo CH Mov Disord; 2017 Jan; 32(1):134-140. PubMed ID: 27813160 [TBL] [Abstract][Full Text] [Related]
29. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Juh R; Kim J; Moon D; Choe B; Suh T Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329 [TBL] [Abstract][Full Text] [Related]
30. Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy. Maloteaux JM; Luabeya MA; Vanisberg MA; Laterre EC; Laduron PM; Javoy-Agid F; Agid Y Brain Res; 1988 Apr; 446(2):321-32. PubMed ID: 2836033 [TBL] [Abstract][Full Text] [Related]
31. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Chinaglia G; Landwehrmeyer B; Probst A; Palacios JM Neuroscience; 1993 Jun; 54(3):691-9. PubMed ID: 8332256 [TBL] [Abstract][Full Text] [Related]
32. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699 [TBL] [Abstract][Full Text] [Related]
33. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Perry TL; Yong VW Neurosci Lett; 1986 Jun; 67(3):269-74. PubMed ID: 3737015 [TBL] [Abstract][Full Text] [Related]
34. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Halliday GM; Macdonald V; Henderson JM Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651 [TBL] [Abstract][Full Text] [Related]
35. Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration. Malessa S; Hirsch EC; Cervera P; Duyckaerts C; Agid Y Neurology; 1990 Nov; 40(11):1739-43. PubMed ID: 1978260 [TBL] [Abstract][Full Text] [Related]
36. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926 [TBL] [Abstract][Full Text] [Related]
37. Qualitative postural control differences in Idiopathic Parkinson's Disease vs. Progressive Supranuclear Palsy with dynamic-on-static platform tilt. Kammermeier S; Maierbeck K; Dietrich L; Plate A; Lorenzl S; Singh A; Bötzel K; Maurer C Clin Neurophysiol; 2018 Jun; 129(6):1137-1147. PubMed ID: 29631169 [TBL] [Abstract][Full Text] [Related]
38. [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy. Holemans S; Javoy F; Agid Y; Laterre EC; Maloteaux JM Brain Res; 1991 Nov; 565(1):154-7. PubMed ID: 1837752 [TBL] [Abstract][Full Text] [Related]
39. Analysis of Extrastriatal Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628 [No Abstract] [Full Text] [Related]
40. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Federico F; Simone IL; Lucivero V; Iliceto G; De Mari M; Giannini P; Mezzapesa DM; Tarantino A; Lamberti P Mov Disord; 1997 Nov; 12(6):903-9. PubMed ID: 9399213 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]